- Home
- RSF vs SER Comparison
RSF vs SER Comparison
Compare RSF & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSF
- SER
- Stock Information
- Founded
- RSF 2016
- SER 2017
- Country
- RSF United States
- SER United States
- Employees
- RSF N/A
- SER N/A
- Industry
- RSF Investment Managers
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- RSF Finance
- SER Health Care
- Exchange
- RSF Nasdaq
- SER Nasdaq
- Market Cap
- RSF 52.3M
- SER 56.5M
- IPO Year
- RSF N/A
- SER 2018
- Fundamental
- Price
- RSF $14.66
- SER $5.85
- Analyst Decision
- RSF
- SER Strong Buy
- Analyst Count
- RSF 0
- SER 1
- Target Price
- RSF N/A
- SER $11.00
- AVG Volume (30 Days)
- RSF 11.8K
- SER 17.8K
- Earning Date
- RSF 01-01-0001
- SER 08-08-2025
- Dividend Yield
- RSF 10.61%
- SER N/A
- EPS Growth
- RSF N/A
- SER N/A
- EPS
- RSF N/A
- SER N/A
- Revenue
- RSF N/A
- SER $51,000.00
- Revenue This Year
- RSF N/A
- SER N/A
- Revenue Next Year
- RSF N/A
- SER N/A
- P/E Ratio
- RSF N/A
- SER N/A
- Revenue Growth
- RSF N/A
- SER N/A
- 52 Week Low
- RSF $14.81
- SER $3.81
- 52 Week High
- RSF $16.23
- SER $12.69
- Technical
- Relative Strength Index (RSI)
- RSF 37.25
- SER 50.74
- Support Level
- RSF $14.63
- SER $5.78
- Resistance Level
- RSF $14.79
- SER $6.30
- Average True Range (ATR)
- RSF 0.08
- SER 0.35
- MACD
- RSF -0.00
- SER -0.03
- Stochastic Oscillator
- RSF 13.29
- SER 36.74
About RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.